PM1183-C-008-21-Lagoon

Research code: PM1183-C-008-21-Lagoon

Research name:  Randomized, multicenter, open-label Phase III study of lurbinectin monotherapy or lurbinectin in combination with irinotecan compared with investigator's choice (topotecan or irinotecan) in patients with recurrent small cell lung cancer (SCLC)

Indication: Lung cancer Principal Investigator 
Principal researcher: Ewa Chmielowska, MD, PhD
Research population: Patients with recurrent small-cell lung cancer (SCLC)
Investigational Drug: Topotecan or irinotecan